SCHEMBL11030461

SCHEMBL11030461

COc1cc(N2CCN(CCN3CCOCC3)CC2)ccc1Nc1cc(Cc2c(F)cccc2Cl)cnc1C(N)=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 9/20 0.51
▸ JAK2 O60674 3/20 0.51
▸ TNK2 Q07912 2/20 0.51
▸ SRC P12931 1/20 0.51
▸ MAPK10 P53779 5/20 0.48
▸ MAPK9 P45984 4/20 0.48
▸ MAPK8 P45983 2/20 0.48
▸ ZAP70 P43403 1/20 0.47
▸ EGFR P00533 4/20 0.45
▸ JAK1 P23458 1/20 0.45
▸ TYK2 P29597 1/20 0.45
▸ JAK3 P52333 1/20 0.45
▸ LRRK2 Q5S007 2/20 0.45
▸ INSR P06213 2/20 0.45
▸ CDC7 O00311 1/20 0.45
▸ PLK4 O00444 1/20 0.45
▸ CHEK1 O14757 1/20 0.45
▸ AURKA O14965 1/20 0.45
▸ DCLK1 O15075 1/20 0.45
▸ PDPK1 O15530 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11034031 0.91 ALK (0.49) ALKJAK2TNK2SRCMAPK10
SCHEMBL11033146 0.91 ALK (0.58) ALKJAK2TNK2SRCEGFR
SCHEMBL11031108 0.90 ALK (0.47) ALKJAK2TNK2SRCEGFR
SCHEMBL11028789 0.89 ALK (0.47) ALKJAK2TNK2SRCMAPK10
SCHEMBL11030660 0.88 ALK (0.55) ALKJAK2TNK2SRCEGFR
SCHEMBL11027989 0.86 CCNT1 (0.53) ALKJAK2TNK2SRCEGFR
SCHEMBL11027391 0.85 ALK (0.54) ALKJAK2TNK2SRCEGFR
SCHEMBL11029807 0.82 ALK (0.60) ALKEGFR
SCHEMBL11029039 0.80 JAK2 (0.52) ALKJAK2TNK2SRCEGFR
SCHEMBL11028993 0.80 ALK (0.57) ALKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 ALK 1/4885JAK2 83/4885TNK2 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback